NEW YORK (GenomeWeb) - Nanosphere today announced after the close of the market that its third quarter revenues rose 33 percent on sales of its Verigene Gram Positive and Gram Negative Blood Culture Tests.

For the three months ended Sept. 30, the Northbrook, Illinois-based molecular diagnostics company said it posted record-high revenues of $4.9 million, up from $3.7 million a year ago, and in line with the average Wall Street expectation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.